Kedrion and LFB are joining forces in an industrial cooperation agreement to increase the availability of Immunoglobulin, a plasma-derived medicine, for patients in France.
According to the agreement, Kedrion will manufacture Immunoglobulins in Hungary from LFB plasma collected in France by the Etablissement Français du Sang. These Immunoglobulins manufactured by Kedrion will be imported by LFB in France and will complement LFB’s own Immunoglobulins, which will be made available to hospitals throughout the country, in agreement with and under the control of French health authorities.
“I am delighted with this partnership with Kedrion, which will enable us to meet the growing needs of the French market for Immunoglobulins, drugs that are in great demand in France and around the world“, emphasized Denis Delval, LFB’s Chairman and CEO. “Our agreement with Kedrion will provide us with an additional supply of Immunoglobulins for patients in France“.
Paolo Marcucci, President of Kedrion, commented, “I welcome the cooperation agreement with LFB as it provides a solution for patients in France. Kedrion shares LFB’s values and its raison d’être, which is to provide products and therapies to patients with serious and often rare diseases“.